Hypoalphalipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
imported>Caesar Schinas (remove broken template) |
imported>Robert Badgett mNo edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Hypoalphalipoproteinemias''', also called ''familial high density lipoprotein deficiency disease'' and ''HDL lipoprotein deficiency disease'', are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density | '''Hypoalphalipoproteinemias''', also called ''familial high density lipoprotein deficiency disease'' and ''HDL lipoprotein deficiency disease'', are defined as "conditions with abnormally low levels of alpha-lipoproteins ([[high-density lipoprotein]]s) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding [[apolipoprotein A-I]]; [[lecithin cholesterol acyltransferase]]; and ATP-binding cassette transporters."<ref name="MeSH-Hypoalphalipoproteinemias ">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=Hypoalphalipoproteinemias |title=Hypoalphalipoproteinemias |accessdate=2007-12-17 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> | ||
==Treatment== | ==Treatment== | ||
Revision as of 05:12, 18 November 2009
Hypoalphalipoproteinemias, also called familial high density lipoprotein deficiency disease and HDL lipoprotein deficiency disease, are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein A-I; lecithin cholesterol acyltransferase; and ATP-binding cassette transporters."[1]
Treatment
Using gemfibrozil to treat hypoalphalipoproteinemia may reduce major cardiovascular events[2] and stroke[3] and in men with known men with known coronary heart disease.
Using simvastatin plus niacin to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with coronary heart disease.[4]
References
- ↑ National Library of Medicine. Hypoalphalipoproteinemias. Retrieved on 2007-12-17.
- ↑ Rubins HB, Robins SJ, Collins D, et al (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259. [e]
- ↑ Bloomfield Rubins H, Davenport J, Babikian V, et al (2001). "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)". Circulation 103 (23): 2828–33. PMID 11401940. [e]
- ↑ Brown BG, Zhao XQ, Chait A, et al (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504. [e]